In a victory for Teva Pharmaceutical Industries, the U.S. Supreme Court today refused to revive Helsinn Healthcare S.A.’s patent on an anti-nausea drug Aloxi.

The decision was unanimously upheld in a lower court ruling which canceled Helsinn’s patent on the drug for violating a provision in U.S. patent law that forbids sales of an invention before applying for a patent.

Teva launched its generic version of the drug in March 2018 after the lower court invalidated the patent.

The Patent Lawyer - Logo

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!